MedTrace Logo

Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI

NCT07583784 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 860

Last updated 2026-05-13

No results posted yet for this study

Summary

The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).

Conditions

  • Myocardial Infarction (MI)
  • ST-Segment Elevation Myocardial Infarction(STEMI)
  • NSTEMI - Non-ST-Segment Elevation Myocardial Infarction
  • AF - Atrial Fibrillation

Interventions

DRUG

DAT (DOAC+clopidogrel)

Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.

DRUG

DOAC monotherapy

Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily.

Sponsors & Collaborators

  • Chonnam National University Hospital

    lead OTHER

Principal Investigators

  • Young Joon Hong, MD, PhD · Chonnam National University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2031-12-31
Completion
2032-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07583784 on ClinicalTrials.gov